VivoSeq
Other

TED

0

Pipeline Programs↗

46

Active Trials↗

66

Companies Involved↗

TED is an early-stage landscape with 0 programs across 66 companies. The most active players are Boehringer Ingelheim, Merck & Co., GSK.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

36/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

447

clinical trials

Completed325 · 73%
Terminated35 · 8%
Unknown status32 · 7%
Recruiting26 · 6%
Not yet recruiting9 · 2%
Withdrawn8 · 2%
Other12 · 3%

Clinical Trials

Trial Activity

447 trials

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Recruiting·UUniversity Medical Center Groningen·Phase 4·NCT05525338·196 enrolled
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Recruiting·MMassachusetts General Hospital·Phase 2·NCT06561347·55 enrolled
Biological Collection for Marfan and Related Syndromes
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT04970459·300 enrolled
The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients
Recruiting·UUniversità Vita-Salute San Raffaele·Phase 3·NCT06503016·400 enrolled
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05870475·94 enrolled
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Recruiting·UUniversity of California, Davis·Phase 1·NCT06228482·40 enrolled
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Recruiting·SSociedad Española de Medicina Nuclear e Imagen Molecular·N/A·NCT04949282·5,000 enrolled
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Recruiting·AAscendis Pharma Endocrinology Division A/S·N/A·NCT05775523·500 enrolled
Epcoritamab in Previously Treated WM
Recruiting·GGottfried von Keudell, MD PhD·Phase 2·NCT06510491·20 enrolled
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Recruiting·—·Phase 2·NCT06959732·40 enrolled
A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06916702·60 enrolled
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06745297·142 enrolled
Defecation Patterns in Constipated Patients
Recruiting·TThe California Medical Innovations Institute, Inc.·N/A·NCT04903470·130 enrolled
Page 1 of 30

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)